

Erratum to: Abstracts of the 53rd Annual Meeting of the EASD, Lisbon 2017. Abstract 788: 'Pharmacokinetics and tolerability of oral semaglutide in subjects with renal impairment'

T. W. Anderson¹ · C. Granhall¹ · Á. Réthy² · F. L. Søndergaard¹ · M. Thomsen¹

© Springer-Verlag GmbH Germany 2017

Erratum to: Diabetologia

<http://dx.doi.org/10.1007/s00125-017-4350-z>

T.W. Anderson¹, C. Granhall¹, Á. Réthy², F.L. Søndergaard¹, M. Thomsen¹

¹Novo Nordisk, Søborg, Denmark, ²Péterfy Sándor utcai Kórház, Budapest, Hungary.

The original version of this abstract unfortunately contained a mistake. Instead of a table a figure was erroneously published. The correct table is given below.

Semaglutide exposure in subjects with renal impairment versus subjects with normal renal function

	AUC _{0-24h, Day 10} Ratio [90% CI]	C _{max, Day 10} Ratio [90% CI]
Mild vs. Normal	1.37 [0.91;2.06]	1.39 [0.93;2.06]
Moderate vs. Normal	1.13 [0.69;1.84]	1.20 [0.75;1.93]
Severe vs. Normal	0.61 [0.42;0.88]	0.61 [0.42;0.87]
ESRD vs. Normal	1.02 [0.59;1.79]	1.06 [0.61;1.84]

AUC_{0-24h, Day 10}: Area under the semaglutide plasma concentration-time curve from 0 to 24 hours after the 10th daily dose

C_{max, Day 10}: Maximum semaglutide plasma concentration after the 10th daily dose

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00125-017-4350-z>

✉ T. W. Anderson

¹ Novo Nordisk, Søborg, Denmark

² Péterfy Sándor utcai Kórház, Budapest, Hungary